17019-92-0 Usage
Description
11-KETO-BETA-BOSWELLIC ACID is a bioactive compound found in the resin of Boswellia trees, commonly known as frankincense. It possesses potent anti-inflammatory properties and has been demonstrated to exhibit significant therapeutic effects in various medical applications.
Uses
Used in Pharmaceutical Industry:
11-KETO-BETA-BOSWELLIC ACID is used as an anti-inflammatory agent for its ability to reduce inflammation and alleviate pain associated with various conditions. Its mechanism of action involves inhibiting the activity of key inflammatory enzymes and pathways, leading to a decrease in inflammation and associated symptoms.
Used in Cancer Therapy:
11-KETO-BETA-BOSWELLIC ACID is used as an apoptosis inducer in cancer treatment, particularly for colon cancer cells. It has been shown to trigger apoptosis via a caspase-8 dependent pathway, which is independent of the Fas/Fas ligand interaction. This selective targeting of cancer cells makes it a promising candidate for cancer therapy, potentially offering a non-toxic and effective treatment option.
Biological Activity
37.9 μm: blocks a2780 (cis-platin resistant ovarian cancer cells) [1].11-keto-β-boswellic acid, known as kba, is a naturally occurring pentacyclic triterpene isolated from the gum resin of the tree boswellia serrata. kba is non-redox, specific leukotriene synthesis inhibitors through the inhibition of 5-lipoxygenase (5-lox) which has anti-arthritic and anti-inflammatory activities. 5-lox catalyzes essential fatty acids substrates into leukotrienes and a variety of other biologically active products. kba is a novel activator of nuclear factor erythroid-2-related factor 2 (nrf2), which protects against cerebral ischemic injury.
in vitro
kba, concentration dependently, decreased the formation of leukotriene b4 and the synthesis of all 5-lox products from endogenous arachidonic acid in rat peritoneal neutrophils. in contrast, kba exerted no remarkable effects on the 12-lipoxygenase and cyclooxygenase activities. [2].
in vivo
adult male sprague–dawley rats were injected kab intraperitoneally at a dose of 25 mg/kg for 48 hours. kab remarkably decreased infarct volumes as well as apoptotic cells at 1 h, and then increased neurologic scores when applied 48 h. moreover, posttreatment with kba induced the decrease of malondialdehyde levels and the increase of protein nrf2 and heme oxygenase-1 expression in brain tissues, indicating that the nrf2/ho-1 pathway was involved in the neuroprotection of kba against oxidative stress-induced ischemic injury [3].
IC 50
35.8 μm: inhibits mcf-7 (human breast adenocarcinoma) [1].
references
[1]. csuk, r., barthel-niesen, a., barthel, a., schffer, r., & al-harrasi, a. 11-keto-boswellic acid derived amides and monodesmosidic saponins induce apoptosis in breast and cervical cancers cells. european journal of medicinal chemistry. 2015; 100: 98-105. [2]. safayhi, h., mack, t. h. o. m. a. s., sabieraj, j. o. a. c. h. i. m., anazodo, m. i., subramanian, l. r., & ammon, h. p. boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. journal of pharmacology and experimental therapeutics. 1992; 261(3):1143-1146.[3]. ding, y., chen, m., wang, m., li, y., & wen, a. posttreatment with 11-keto-β-boswellic acid ameliorates cerebral ischemia–reperfusion injury: nrf2/ho-1 pathway as a potential mechanism. molecular neurobiology. 2014; 52(3): 1430-1439.
Check Digit Verification of cas no
The CAS Registry Mumber 17019-92-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,0,1 and 9 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 17019-92:
(7*1)+(6*7)+(5*0)+(4*1)+(3*9)+(2*9)+(1*2)=100
100 % 10 = 0
So 17019-92-0 is a valid CAS Registry Number.
InChI:InChI=1/C30H46O4/c1-17-8-11-26(3)14-15-28(5)19(23(26)18(17)2)16-20(31)24-27(4)12-10-22(32)30(7,25(33)34)21(27)9-13-29(24,28)6/h16-18,21-24,32H,8-15H2,1-7H3,(H,33,34)/t17-,18+,21-,22-,23+,24-,26-,27+,28-,29-,30-/m1/s1
17019-92-0Relevant articles and documents
NOVEL SALTS OF BOSWELLIC ACIDS AND SELECTIVELY ENRICHED BOSWELLIC ACIDS AND PROCESSES FOR THE SAME
-
Page/Page column 12, (2008/06/13)
The present invention relates to new salts or ion ion-pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-?-boswellic acid (AKBA) or 11-keto-?-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also used in cosmetic or pharmaceutical composition for external body part or organ to treat inflammatory diseases or cancer.